EP3145913A1 - Nouveaux polymorphes de (s)-malate de cabozantinib et cabozantinib sous forme de base libre - Google Patents

Nouveaux polymorphes de (s)-malate de cabozantinib et cabozantinib sous forme de base libre

Info

Publication number
EP3145913A1
EP3145913A1 EP15728635.2A EP15728635A EP3145913A1 EP 3145913 A1 EP3145913 A1 EP 3145913A1 EP 15728635 A EP15728635 A EP 15728635A EP 3145913 A1 EP3145913 A1 EP 3145913A1
Authority
EP
European Patent Office
Prior art keywords
cabozantinib
solvent
malate
process according
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15728635.2A
Other languages
German (de)
English (en)
Inventor
Ramakoteswara Rao Jetti
Anjaneyaraju Indukuri
Dnyandeo PUNDE
Chandersingh BOHRA
Mahesh Kumar GADAKAR
Vinayak Gore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mylan Laboratories Ltd
Original Assignee
Mylan Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Ltd filed Critical Mylan Laboratories Ltd
Publication of EP3145913A1 publication Critical patent/EP3145913A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates generally to novel crystalline forms of cabozantinib (S)-malate, designated as form-Mi, M 2 , M 3 , and M 4 and novel crystalline forms of cabozantinib free base, form-Mi, M 2 and M 3 .
  • the present invention also relates to process for the preparation of crystalline forms of cabozantinib (S)-malate, designated as form-Mi, M 2 , M 3 , and M 4 and novel crystalline forms of cabozantinib free base, form-Mi, M 2 and M 3 as well as crystalline cabozantinib (S)-malate form N-l .
  • Cabozantinib (S)-malate chemically known as N-(4-(6, 7-dimethoxyquinolin-4-yloxy) phenyl)- N'-(4-fluorophenyl) cyclopropane- 1, 1 -dicarboxamide (S)-malate is structurally represented as Formula-I below.
  • Cabozantinib is marketed under the trade name COMETRIQ® by Exelixis, Inc. COMETRIQ® is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
  • the present invention provides novel crystalline forms of cabozantinib (S)-malate and novel crystalline forms of cabozantinib free base.
  • One aspect of the present invention provides novel crystalline forms-Mi, M 2 , M 3 and M4 of cabozantinib (S)-malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the steps of:
  • step (a) a) dissolving cabozantinib (S)-malate in a solvent or mixture of solvents, b) adding the above solution of step (a) to non-polar solvent, and
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the steps of:
  • step (a) adding the above solution of step (a) to non-polar solvent, and
  • Another embodiment of the present invention a process for the preparation of crystalline form- Mi of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in a polar solvent,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M 3 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in a polar solvent,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M 4 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the solution to a non-polar solvent, and
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M 4 of cabozantinib (S)-malate which includes the steps of: a) dissolving cabozantinib (S)-malate in an amide solvent,
  • Another aspect of the present invention provides novel crystalline forms-Mi, M 2 and M 3 of cabozantinib free base.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the steps of: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the steps of: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M2 of cabozantinib free base which includes the steps of: a) dissolving cabozantinib in a solvent,
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M3 of cabozantinib free base which includes the steps of: a) providing cabozantinib base in an ester solvent,
  • Yet another aspect of the present invention provides a process for the preparation of crystalline cabozantinib (S)-malate form N-l which includes the steps of: a) providing cabozantinib base and (S)-malic acid in a first polar solvent, b) adding second solvent,
  • FIGURE 1 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-Mi;
  • FIGURE 2 is a DSC thermogram of crystalline cabozantinib (S)-malate form-Mi;
  • FIGURE 3 is a TGA trace of crystalline cabozantinib (S)-malate form-Mi;
  • FIGURE 4 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-M 2
  • FIGURE 5 is a DSC thermogram of crystalline cabozantinib (S)-malate form-M 2 ;
  • FIGURE 6 is a TGA trace of crystalline cabozantinib (S)-malate form-M 2 ;
  • FIGURE 7 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-M 3 ;
  • FIGURE 8 is a powder X-ray diffraction pattern of crystalline cabozantinib (S)-malate form-Mt;
  • FIGURE 9 is a DSC thermogram of crystalline cabozantinib (S)-malate form-Mt;
  • FIGURE 10 is a TGA trace of crystalline cabozantinib (S)-malate form-Mt;
  • FIGURE 11 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-Mi;
  • FIGURE 12 is a DSC thermogram of crystalline cabozantinib free base form-Mi;
  • FIGURE 13 is a TGA trace of crystalline cabozantinib free base form-Mi;
  • FIGURE 14 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-M 2 ;
  • FIGURE 15 is a DSC thermogram of crystalline cabozantinib free base form-M 2 ;
  • FIGURE 16 is a TGA trace of crystalline cabozantinib free base form-M 2 ;
  • FIGURE 17 is a powder X-ray diffraction pattern of crystalline cabozantinib free base form-M3.
  • the present disclosure provides novel crystalline forms-Mi, M 2 , M3 and M4 of cabozantinib (S)- malate and crystalline forms-Mi, M 2 and M3 of cabozantinib free base.
  • the present disclosure also provides processed for the preparation of crystalline forms-Mi, M 2 , M3 and M4 of cabozantinib (S)-malate and crystalline forms-Mi, M 2 and M3 of cabozantinib free base as well as crystalline cabozantinib (S)-malate form N-l.
  • One aspect of the present invention provides crystalline form-Mi of cabozantinib (S)-malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
  • step (b) adding the above solution of step (a) to a non-polar solvent, and
  • cabozantinib (S)-malate may be dissolved in a solvent to create a solution.
  • the solvent used for dissolving cabozantinib (S)-malate may be, for example, ethereal, alcoholic, water, or mixtures thereof.
  • suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol.
  • a mixture of tetrahydrofuran and water was found to be a particularly useful solvent for dissolving cabozantinib (S)-malate.
  • the solution of cabozantinib (S)-malate may be added to a non-polar solvent.
  • the non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes.
  • n-heptane was found to be a particularly useful non-polar solvent.
  • the obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
  • cabozantinib (S)-malate may be dissolved in tetrahydrofuran and water at a temperature of about 55°C to about 70°C. The reaction temperature may then be cooled to room temperature. The resulting clear solution may then be added to a non-polar solvent such as n-heptane. The obtained solid may be filtered and dried to get the crystalline form-Mi of cabozantinib (S)-malate.
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib (S)-malate which includes the following steps:
  • step (a) a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the above solution of step (a) to non-polar solvent, and
  • cabozantinib base and (S)-malic acid may be dissolved in a solvent.
  • the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or a mixture thereof.
  • suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • suitable alcohols include methanol, ethanol, propanol, and butanol. In some embodiments of the present invention, a mixture of tetrahydrofuran and water was found to be particularly useful.
  • tetrahydrofuran and water in a ratio of 12: 1 was found to be particularly useful.
  • the solution of cabozantinib (S)-malate may be added to a non-polar solvent.
  • the non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes.
  • n-heptane was found to be a particularly useful non-polar solvent.
  • the obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
  • cabozantinib base and (S)-malic acid may be dissolved in a mixture of solvents such as tetrahydrofuran and water at a temperature between about 55°C to about 70°C. The temperature of the solution may then be cooled to room temperature. The resulting clear solution may then be added to non-polar solvent, for example, n-heptane, at about 20°C to about 35°C. The obtained solid may then be filtered and dried under vacuum to get the crystalline form-Mi of cabozantinib (S)-malate.
  • solvents such as tetrahydrofuran and water
  • the crystalline polymorph forms of compounds disclosed in the present invention may be characterized by X-ray powder diffraction ("XRPD") pattern.
  • XRPD X-ray powder diffraction
  • the XRPD patterns were measured on BRUKER D-8 Discover powder diffractometer equipped with goniometer of ⁇ /2 ⁇ configuration and Lynx Eye detector.
  • the Cu-anode X-ray tube was operated at 40kV and 30mA. The experiments were conducted over the 2 ⁇ range of 2.0°-50.0°, 0.030° step size and 0.4 seconds step time.
  • crystalline form-Mi of cabozantinib (S)-malate may be characterized by an XRPD pattern having characteristic peak at about 13.2 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form-Mi of cabozantinib (S)-malate may be further characterized by the XRPD pattern in FIGURE 1.
  • the crystalline polymorph forms of compounds disclosed in the present invention may also be characterized by differential scanning calorimetry (DSC).
  • DSC differential scanning calorimetry
  • the DSC measurements were carried out on TA Q1000 of TA Instruments. The experiments were performed at a heating rate of 20.0 °C/min over a temperature range of 30°C-330°C purging with nitrogen at a flow rate of 50 ml/min. Standard aluminum crucibles covered by lids with pin holes were used.
  • the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the DSC thermogram in FIGURE 2.
  • the crystalline polymorph forms of compounds disclosed in the present invention may also be characterized by thermogravimetric analysis (TGA).
  • TGA thermogravimetric analysis
  • TGA/DTA was recorded using the instrument TA Q5000 IR of TA Instruments. The experiments were performed at a heating rate of 10.0 °C/min over a temperature range of 30°C- 350°C purging with nitrogen at a flow rate of 25 ml/min.
  • the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the TGA trace in FIGURE 3.
  • Another aspect of the present invention provides crystalline form-M 2 of cabozantinib (S)-malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M 2 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a polar solvent to create a solution,
  • cabozantinib (S)-malate may be dissolved in a polar solvent.
  • the polar solvent may be, for example, formic acid, acetic acid, or propionic acid.
  • propionic acid is a particularly useful solvent.
  • an ethereal solvent may be added to the reaction mass.
  • the ethereal solvent may be, for example, dimethyl ether, diethyl ether, ethyl methyl ether, methyl-t-butyl ether, tetrahydrofuran, or 1,4-dioxane.
  • methyl-t- butyl ether was found to be a particularly useful solvent. Crystalline form-M 2 of cabozantinib (S)-malate may then be isolated.
  • cabozantinib (S)-malate may be dissolved in a polar solvent such as propionic acid at temperature about 45°C to about 55°C and then cooled to about 20°C to about 35°C.
  • An ethereal solvent such as methyl-t-butyl ether may then be added to the reaction mixture.
  • the obtained solid may then be filtered and dried to get the crystalline form-M 2 of cabozantinib (S)-malate.
  • crystalline form-M 2 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks at 8.5, 12.5, 20.2, 23.1, and 26.1 ( ⁇ ) 0.2° 2-theta.
  • crystalline form-M 2 of cabozantinib (S)-malate may be further characterized by XRPD pattern having characteristic peaks at 8.5, 12.5, 14.3, 20.2, 22.2, 23.1, 26.1, 26.6, and 26.9 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form-M 2 of cabozantinib (S)-malate may be further characterized by the XRPD pattern in FIGURE 4.
  • the crystalline form-M 2 of cabozantinib (S)-malate may also be characterized by the DSC thermogram in FIGURE 5.
  • the crystalline form-M 2 of cabozantinib (S)-malate may additionally be characterized by the TGA trace in FIGURE 6.
  • Another aspect of the present invention provides crystalline form-M3 of cabozantinib (S)-malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M 3 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in a polar solvent to create a solution,
  • cabozantinib (S)-malate may be dissolved in a polar solvent.
  • the polar solvent may be, for example, formic acid, acetic acid, or propionic acid.
  • acetic acid was found to be a particularly useful polar solvent.
  • cabozantinib (S)-malate may be dissolved in a polar solvent, such as acetic acid, at a temperature between about 55°C and about 65°C.
  • a polar solvent such as acetic acid
  • the resulting clear solution may be cooled to about -5°C to about 10°C, and water may be added to the reaction mass.
  • the obtained solid may then be filtered and washed with water to get the crystalline form-M3 of cabozantinib (S)-malate.
  • crystalline form-M3 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks, 11.9, 12.6, and 18.1 ( ⁇ ) 0.2° 2- theta.
  • crystalline form-M3 of cabozantinib (S)-malate may be further characterized by the XRPD pattern having characteristic peaks at 6.3, 9.1, 11.9, 12.6, 13.6, 15.1, 16.9, 18.1, 19.1, 21.2, 23.7, 25.8, 27.5, 30.1 , and 31.0 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form- M 3 of cabozantinib (S)-malate may also be further characterized by the powder X-ray diffractogram in FIGURE 7.
  • Another aspect of the present invention provides the crystalline form-Mi of cabozantinib (S)- malate.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M 4 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib base and (S)-malic acid in a solvent to create a solution, b) adding the above solution of step (a) to a non-polar solvent,
  • cabozantinib base and (S)-malic acid may be dissolved in a solvent.
  • the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or a mixture thereof.
  • suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol.
  • a mixture of tetrahydrofuran and water was found to be particularly useful.
  • a ratio of 15: 1 tetrahydrofuran to water was found to be particularly useful.
  • the solution of cabozantinib (S)-malate may be added to a non-polar solvent.
  • the non- polar solvent may be, for example, a Ci-Cio alkane or a mixture of Ci-Cio alkanes.
  • n-heptane was found to be a particularly useful non-polar solvent.
  • the obtained solid may then be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
  • cabozantinib base and (S)-malic acid may be dissolved in a mixture of solvents, such as tetrahydrofuran and water, at a temperature between about 55°C and about 70°C.
  • the reaction temperature may then be cooled to room temperature.
  • the resulted clear solution may then be added to a non-polar solvent, for example, n-heptane, at about 45°C to about 60°C.
  • the resulted reaction mass may be cooled to about 20°C to about 35°C.
  • the obtained solid is filtered and dried under vacuum to get the crystalline form-M 4 of cabozantinib (S)-malate.
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-M 4 of cabozantinib (S)-malate which includes the following steps: a) dissolving cabozantinib (S)-malate in an amide solvent to create a solution, b) adding a solvent to the solution, and
  • cabozantinib (S)-malate may be dissolved in an amide solvent to create a solution.
  • the amide solvent may be, for example, N,N-dimethylacetamide, ⁇ , ⁇ -dimethylformamide, or N-methylpyrrolidone.
  • ⁇ , ⁇ -dimethylacetamide was found to be a particularly useful solvent.
  • a solvent may be added to the solution.
  • the solvent may be, for example, an ethereal solvent, an alcoholic solvent, water, or mixtures thereof.
  • Suitable ethereal solvents include dimethyl ether, diethyl ether, ethyl methyl ether, methyl-t-butyl ether, tetrahydrofuran, and 1,4-dioxane.
  • suitable alcohol solvents include methanol, ethanol, propanol, and butanol. In some embodiments, a mixture of methyl-t- butyl ether and ethanol was found to be particularly useful.
  • the solid may be isolated to get a crystalline form-Mi of cabozantinib (S)-malate.
  • cabozantinib (S)-malate may be dissolved in an amide solvent such as ⁇ , ⁇ -dimethylacetamide at a temperature between about 45°C and about 55°C to create a clear solution.
  • Methyl-t-butyl ether and ethanol may then be added to the clear solution at room temperature.
  • the obtained solid may then be filtered and dried to get the crystalline form-Mi of cabozantinib (S)-malate.
  • crystalline form-M 4 of cabozantinib (S)-malate may be characterized by the XRPD pattern having characteristic peaks at about 13.3, 15.0, 22.8, and 25.8 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form-M t of cabozantinib (S)-malate may be further characterized by the XRPD pattern having characteristic peaks at 9.3, 13.3, 15.0, 19.5, 20.9, 22.8, 25.8, and 26.9 ( ⁇ ) 0.2° 2- theta.
  • the crystalline form-Mi of cabozantinib (S)-malate may also be characterized by the PXRD pattern in FIGURE 8.
  • the crystalline form-Mi of cabozantinib (S)-malate may be additionally characterized by the DSC thermogram in FIGURE 9.
  • the crystalline form-Mi of cabozantinib (S)-malate may be characterized by the TGA trace in FIGURE 10.
  • Another aspect of the present invention provides the novel crystalline form-Mi of cabozantinib free base.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to create a solution,
  • cabozantinib (S)-malate may be dissolved in a solvent to create a solution.
  • the solvent may be, for example, ⁇ , ⁇ -dimethylacetamide, N,N-dimethylformamide, N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetonitrile, dichloromethane, tetrahydrofuran, or ethyl acetate.
  • N-methyl-2-pyrrolidone was found to be a particularly useful solvent.
  • ketone solvent may be, for example, acetone, methyl ethyl ketone, or methyl isobutyl ketone. In some embodiments of the present invention, acetone was found to be a particularly useful solvent.
  • crystalline form-Mi of cabozantinib free base may then be isolated.
  • cabozantinib (S)-malate may be dissolved in a solvent, such as N-methyl-2-pyrrolidone, at a temperature between about 20°C and about 35°C. Water may then be added to the clear solution. Next, a ketone solvent, for example, acetone, may be added, and the reaction mixture heated to about 45°C to about 55°C. Water may then be added while the reaction mixture is maintained at a temperature between about 20°C and about 35°C. The obtained solid may then be filtered to get the crystalline form-Mi of cabozantinib free base.
  • a solvent such as N-methyl-2-pyrrolidone
  • Another embodiment of the present invention provides a process for the preparation of crystalline form-Mi of cabozantinib free base, which includes the following steps: a) dissolving cabozantinib (S)-malate in a solvent to form a solution,
  • cabozantinib (S)-malate may be dissolved in a solvent to create a solution.
  • the solvent may be, for example, ⁇ , ⁇ -dimethylacetamide, N,N- dimethylformamide, N-methyl-2-pyrrolidone, dimethyl sulfoxide, acetonitrile, dichloromethane, tetrahydrofuran, or ethyl acetate.
  • dimethyl sulfoxide was found to be a particularly useful solvent.
  • cabozantinib (S)-malate may be dissolved in a solvent, for example, in dimethyl sulfoxide, at a temperature of about 20°C to about 35°C. Water may then be added and the obtained solid is filtered to get the crystalline form-Mi of cabozantinib free base.
  • crystalline form-Mi of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 11.8 ( ⁇ ) 0.2° 2-theta.
  • crystalline form-Mi of cabozantinib free base may be further characterized by the XRPD pattern having peaks at about 11.8, 12.8, 14.3, 17.8, and 22.7 ( ⁇ ) 0.2° 2-theta
  • the crystalline form-Mi of cabozantinib free base may be further characterized by the XRPD pattern as depicted in FIGURE 11.
  • the crystalline form-Mi of cabozantinib free base may be characterized by the DSC thermogram in FIGURE 12.
  • the crystalline form-Mi of cabozantinib free base may also be characterized by the TGA trace in FIGURE 13.
  • Another aspect of the present invention provides the novel crystalline form-M 2 of cabozantinib free base.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M 2 of cabozantinib free base which includes the following steps: a) dissolving cabozantinib in a solvent,
  • cabozantinib may be dissolved in a solvent.
  • the solvent may be, for example, halogenated, alcoholic, or a mixture thereof.
  • Suitable halogenated solvents include, for example, dichloromethane and dichloroethane.
  • Suitable alcohols include, for example, methanol, ethanol, propanol, and butanol. In some embodiments of the present invention, a mixture of methanol and dichloromethane was found to be particularly useful.
  • some of the solvent is removed, for example by Evaporation, Heating and Distillation, preferably Distillation.
  • cabozantinib may be dissolved in a mixture of solvents, for example a mixture methanol and dichloromethane, at about 25°C to about 45°C.
  • a mixture of solvents for example a mixture methanol and dichloromethane
  • the resulting clear solution may then be partially distilled out under atmospheric pressure to obtain a slurry.
  • the slurry is then cooled to a temperature between about 20 °C and about 35 °C and filtered to get the crystalline form-M 2 of cabozantinib free base.
  • crystalline form-M 2 of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 12.6, 14.1, 18.5, 22.1, 23.2, 24.1, and 29.0 ( ⁇ ) 0.2° 2-theta.
  • the crystalline form-M 2 of cabozantinib free base may further characterized by the XRPD pattern having peaks at about 7.8, 11.1, 11.5, 12.6, 14.1, 15.4, 17.2, 18.5, 19.2, 21.1, 22.1, 23.2, 24.1, and 29.0 ( ⁇ ) 0.2° 2-theta
  • the crystalline form-M 2 of cabozantinib free base may be further characterized by the XRPD pattern in FIGURE 14.
  • the crystalline form-M 2 of cabozantinib free base may also be characterized by DSC thermogram in FIGURE 15.
  • the crystalline form-M 2 of cabozantinib free base may also be characterized by the TGA trace as in FIGURE 16.
  • Another aspect of the present invention provides the novel crystalline form-M 3 of cabozantinib free base.
  • One embodiment of the present invention provides a process for the preparation of crystalline form-M3 of cabozantinib free base which includes the following steps: a) providing cabozantinib base in an ester solvent,
  • cabozantinib base may be provided in an ester solvent.
  • the ester solvent may be, for example, methyl acetate, ethyl acetate, propyl acetate, or n-butyl acetate.
  • ethyl acetate was found to be a particularly useful ester solvent.
  • the ester solvent may be substantially removed from the reaction mass, for example by Evaporation, Heating and Distillation, preferably Distillation.
  • an ethereal solvent may be added.
  • Suitable ethereal solvents include, as examples, dimethyl ether, diethyl ether, diisopropyl ether, ethyl methyl ether, methyl-tert-butyl ether, tetrahydrofuran, and 1, 4-dioxane.
  • diisopropyl ether was found to be a particularly useful ethereal solvent.
  • crystalline form-M3 of cabozantinib free base may be isolated.
  • cabozantinib base may be provided in an ester solvent, for example, ethyl acetate, is provided. Next, the solvent may be distilled out.
  • crystalline form-M3 of cabozantinib free base may be characterized by the XRPD pattern having peaks at about 15.5, 17.7, 19.6, and 21.1 ( ⁇ ) 0.2° 2- theta.
  • the crystalline form-M 3 of cabozantinib free base may be further characterized by the XRPD pattern having peaks at about 4.9, 9.7, 12.0, 15.5, 17.7, 19.6, 21.1, 23.1, 24.1, and 26.6 ( ⁇ ) 0.2° 2-theta
  • the crystalline form-M3 of cabozantinib free base may also be further characterized by the XRPD pattern in FIGURE 17.
  • Another aspect of the present invention provides a process for the preparation of crystalline cabozantinib (S)-malate form N-1 which includes the following steps: a) providing cabozantinib base and (S)-malic acid in a first polar solvent,
  • cabozantinib base and (S)-malic acid may be provided in a first polar solvent.
  • the first polar solvent may be, for example, methanol, ethanol, propanol, butanol, ethyl acetate, acetone, acetonitrile, dichloromethane, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, 1,4-dioxane, water, or mixtures thereof.
  • a mixture of tetrahydrofuran and water was found to be particularly useful for this step.
  • a second solvent may be added to the reaction mass.
  • the second solvent may be a nitrile solvent, for example, acetonitrile.
  • the solution may then be seeded with Form N-1 of cabozantinib (S)-malate, and Form N-1 of cabozantinib (S)-malate may then be isolated.
  • cabozantinib base and (S)- malic acid may be added to a solvent, for example, a mixture of tetrahydrofuran and water.
  • a solvent for example, a mixture of tetrahydrofuran and water.
  • the suspension may then be heated to about 55°C to about 65 °C and a second solvent, for example, acetonitrile, may be added to the reaction mass.
  • a seed of form N-1 of cabozantinib (S)-malate may then be added to the solution which is then cooled to about 20°C to about 35°C.
  • the resulted solid may then be filtered and dried to get the crystalline form N-1 of cabozantinib (S)- malate.
  • the reaction conditions e.g., reaction time or temperature
  • the reaction conditions may be adjusted to achieve appropriate yield without undertaking undue experimentation and without departing from the scope of the present disclosure.
  • the cabozantinib polymorphs and cabozantinib free base polymorphs of the present invention may be included in capsules for oral administration.
  • pharmaceutically acceptable excipients including microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, fumed silica, and stearic acid.
  • the capsule may have a shell which may contain one or more of the following ingredients: black iron oxide, red iron oxide, and titanium dioxide.
  • the cabozantinib polymorphs and cabozantinib free base polymorphs disclosed herein may be included in formulations prescribed for the treatment of medullary thyroid cancer and progressive, metastatic medullary thyroid cancer, in particular.
  • the cabozantinib polymorphs and cabozantinib free base polymorphs disclosed herein may be formulated as a solid dosage form, such as a capsule, containing about 20 mg to about 80 mg per capsule for administration to patients.
  • Example 1 Preparation of cabozantinib (S)-malate crystalline form-Mi
  • Example 3 Preparation of cabozantinib (S)-malate crystalline form-Mi
  • Cabozantinib (S)-malate (3 g) was dissolved in THF (36 ml) and water (3 ml) mixture at 60-65 °C and then cooled to room temperature. The resulting clear solution was added to n-heptane (120 ml) solution at 25-30 °C and stirred at room temperature for 1 -2 hours. The solid obtained was filtered and dried under vacuum at 45 °C for 5 hours. The product obtained was identified as cabozantinib (S)-malate crystalline form-Mi.
  • Example 4 Preparation of cabozantinib (S)-malate crystalline form-M2
  • Example 6 Preparation of cabozantinib (S)-malate crystalline form-M4 Cabozantinib free base (1 g) and (S)-malic acid (0.32 g) were dissolved in a mixture of THF (15 ml) and water (1 ml) at 60-65 °C for 60 minutes and the reaction mass was cooled to room temperature. The resulting clear solution was added to an n-heptane solution (15 ml) at 50-55 °C and maintained under agitation for 120 minutes. The resulting reaction mass was cooled to 25- 30 °C and maintained for 60 minutes The obtained solid was filtered and washed with n-heptane (10 ml). The resulted product was dried under vacuum at 60 °C for 180 minutes. The obtained product was identified as cabozantinib (S)-malate crystalline form-Mi.
  • Cabozantinib (S)-malate 50 mg was dissolved in 1 -methyl-2-pyrrolidone (0.5 ml) at 25-30 °C and maintained at 25-30 °C for 2 days without agitation. Water (5 ml) was added to the clear solution resulting in a suspension. Acetone (3 ml) was added to the suspension and heated to 50 °C to get clear solution. Water (5 ml) was added to the clear solution under agitation and maintained at 25-30 °C for 2 hours without agitation. The solid obtained was filtered and identified as cabozantinib free base crystalline form-Mi.
  • Example 10 Preparation of cabozantinib free base crystalline form-M2
  • Cabozantinib base (12.0 g) was dissolved in a methanol (120 ml) and dichloromethane (120 ml)) mixture at 28-38 °C.
  • Charcoal (10%) was added to the resulting clear solution, and the reaction mass was filtered through celite bed.
  • the obtained clear filtrate was distilled under atmospheric pressure at 40-45 °C. The distillation continued until about 10 volumes (120 ml) of solution along with the solid remained inside.
  • the slurry was cooled to 25-30 °C. Then after the slurry was stirred at 25-30 °C room temperature for 1.0 hours.
  • the product was filtered and dried under vacuum at 50-55 °C for 2 hours.
  • the product obtained was identified as non-solvated crystalline cabozantinib free base form-M2.
  • Example 11 Preparation of cabozantinib free base crystalline form-M3 l-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarboxylic acid (2.0 g) was reacted with 4-fluoroaniline hydrochloride (1.08 g) in presence of EDC-HC1 (2.8 g), 1- hydroxybenztriazole (1.98 g), and diisopropylethylamine (5 ml) in N,N-dimethylformamide (20 ml). The reaction was stirred overnight. After overnight stirring, the reaction mass was quenched with water (60 ml).
  • the cabozantinib base was extracted with ethyl acetate (80 ml). Ethyl acetate was distilled out completely and diisopropyl ether (30 ml) was added. The slurry obtained was filtered and dried under vacuum at 60 °C for 2 hours. The product obtained was identified as cabozantinib free base form-M3.
  • Example 12 Process for preparation of cabozantinib form N-l
  • Example 13 Process for preparation of amorphous cabozantinib-(S)-malate 100 mg of cabozantinib (S)-malate obtained by the process in example 3 was kept in a static dryer and heated at 110-120 °C under vacuum for 20-30 min. The resulting solid was identified as amorphous cabozantinib (S)-malate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouvelles formes cristallines de (S)-malate de cabozantinib désignées comme forme M1, M2, M3 et M4 et de nouvelles formes cristallines de cabozantinib sous forme de base libre, M1, M2 et M3 ainsi que des procédés pour leur production. La présente invention concerne également des procédés pour la préparation d'une forme cristalline N-1 de (S)-malate de cabozantinib. Formule (I)
EP15728635.2A 2014-05-23 2015-05-22 Nouveaux polymorphes de (s)-malate de cabozantinib et cabozantinib sous forme de base libre Withdrawn EP3145913A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2561CH2014 2014-05-23
PCT/IB2015/053765 WO2015177758A1 (fr) 2014-05-23 2015-05-22 Nouveaux polymorphes de (s)-malate de cabozantinib et cabozantinib sous forme de base libre

Publications (1)

Publication Number Publication Date
EP3145913A1 true EP3145913A1 (fr) 2017-03-29

Family

ID=53385701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15728635.2A Withdrawn EP3145913A1 (fr) 2014-05-23 2015-05-22 Nouveaux polymorphes de (s)-malate de cabozantinib et cabozantinib sous forme de base libre

Country Status (3)

Country Link
US (1) US9815789B2 (fr)
EP (1) EP3145913A1 (fr)
WO (1) WO2015177758A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109922790B (zh) 2016-09-12 2022-06-14 珠海贝海生物技术有限公司 卡博替尼制剂
EP3551612A4 (fr) * 2016-12-07 2020-08-12 MSN Laboratories Private Limited, R&D Center Procédé de préparation de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophényl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate et ses polymorphes
DK3630726T3 (da) * 2017-05-26 2022-03-07 Exelixis Inc Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse
US20210332014A1 (en) * 2018-09-20 2021-10-28 Crystal Pharmaceutical (Suzhou) Co., Ltd. Cabozantinib malate crystal form, preparation method and use thereof
WO2020075196A1 (fr) 2018-10-11 2020-04-16 Cipla Limited Polymorphes de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophényl)cyclopropane-1, 1-dicarboxamide, (s)-malate, leurs procédés de production et leurs utilisations pharmaceutiques
IT202000027678A1 (it) 2020-11-18 2022-05-18 Indena Spa Dispersioni solide amorfe di cabozantinib-(s)-malato e processi per la loro preparazione
TW202302597A (zh) * 2021-03-10 2023-01-16 美商米拉蒂醫療公司 多重酪胺酸激酶抑制劑之結晶鹽、其製備方法及用途
CN115215797B (zh) * 2021-04-15 2024-04-12 成都苑东生物制药股份有限公司 一种苹果酸卡博替尼新晶型及其制备方法
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
EP2387563B2 (fr) * 2009-01-16 2022-04-27 Exelixis, Inc. Sel de malate de n-(4-{[6,7-bis(méthyloxy)quinolin-4-yl]oxy}phényl)-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2015177758A1 *

Also Published As

Publication number Publication date
US20170096395A1 (en) 2017-04-06
US9815789B2 (en) 2017-11-14
WO2015177758A1 (fr) 2015-11-26

Similar Documents

Publication Publication Date Title
US9815789B2 (en) Polymorphs of cabozantinib (S)-malate and cabozantinib free base
US11472773B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
US11149017B2 (en) Solid state forms of apalutamide
AU2015254949A1 (en) Novel polymorphic forms of Vortioxetine and its pharmaceutically acceptable salts
US20180282351A1 (en) Amorphous Ixazomib Citrate
EP2603503A1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
WO2016016766A2 (fr) Procédé de préparation d'isavuconazonium ou de son sel
JP2021105003A (ja) 多形体及びキナゾリニル誘導体の調製プロセス
KR20180018551A (ko) 아파티닙 유리 염기 및 아파티닙 디말레에이트의 다형체 형태
WO2019003249A1 (fr) Formes polymorphes de baricitinib
US11390637B2 (en) Salts of antiviral phosphonate analogues and process for preparation thereof
WO2015049698A2 (fr) Procédé pour le régorafénib
KR20160126697A (ko) 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
US20180030038A1 (en) Polymorphic Forms of Afatinib Dimaleate
CA2811912A1 (fr) Nouveaux polymorphes de febuxostat
US20200407382A1 (en) Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
AU2010299484A1 (en) Polymorphs of sorafenib acid addition salts
WO2018042320A1 (fr) Sels de betrixaban et leurs procédés de préparation
JP2019529410A (ja) 純粋で安定な結晶のラルテグラビルカリウム３型の製造方法
WO2017093789A1 (fr) Formes polymorphes de dimaléate d'afatinib
US20210040031A1 (en) Process for the preparation of Safinamide Mesylate intermediate
WO2017029408A1 (fr) Formes solides de sofosbuvir
JP2021531329A (ja) ベンゾチオフェン化合物のマレイン酸塩、その結晶形式及びその用途
KR20160143407A (ko) 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
WO2016038590A1 (fr) Procédé de préparation de la forme cristalline i du régorafénib

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
PUAG Search results despatched under rule 164(2) epc together with communication from examining division

Free format text: ORIGINAL CODE: 0009017

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180605

B565 Issuance of search results under rule 164(2) epc

Effective date: 20180605

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20180531BHEP

Ipc: C07D 215/233 20060101AFI20180531BHEP

Ipc: A61K 31/47 20060101ALI20180531BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20181218